TRACON Pharmaceuticals TOYOTA Bond

TCONDelisted Stock  USD 1.60  0.55  52.38%   
TRACON Pharmaceuticals holds a debt-to-equity ratio of 0.354. With a high degree of financial leverage come high-interest payments, which usually reduce TRACON Pharmaceuticals' Earnings Per Share (EPS).

Asset vs Debt

Equity vs Debt

TRACON Pharmaceuticals' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. TRACON Pharmaceuticals' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps TRACON Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect TRACON Pharmaceuticals' stakeholders.
For most companies, including TRACON Pharmaceuticals, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for TRACON Pharmaceuticals, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, TRACON Pharmaceuticals' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
  
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
View Bond Profile
Given the importance of TRACON Pharmaceuticals' capital structure, the first step in the capital decision process is for the management of TRACON Pharmaceuticals to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of TRACON Pharmaceuticals to issue bonds at a reasonable cost.
Popular NameTRACON Pharmaceuticals TOYOTA 19 12 SEP 31
SpecializationBiotechnology
Equity ISIN CodeUS89237H2094
Bond Issue ISIN CodeUS89236TJQ94
View All TRACON Pharmaceuticals Outstanding Bonds

TRACON Pharmaceuticals Outstanding Bond Obligations

TOYOTA 365 18 AUG 25US89236TKF11Details
TOYOTA 445 29 JUN 29US89236TKD62Details
TOYOTA 395 30 JUN 25US89236TKC89Details
TOYOTA 2362 25 MAR 31US892331AN94Details
TOYOTA 305 22 MAR 27US89236TJZ93Details
TOYOTA 24 13 JAN 32US89236TJW62Details
US892356AA40US892356AA40Details
Dana 575 percentUS235822AB96Details
TOYOTA 19 13 JAN 27US89236TJV89Details
TOYOTA 483428 13 JAN 25US89236TJU07Details
TOYOTA MOTOR PORATIONUS892331AM12Details
TOYOTA 145 13 JAN 25US89236TJT34Details
TOYOTA 19 12 SEP 31US89236TJQ94Details
Toyota Motor CorpUS892331AG44Details
TOYOTA MTR PUS892331AD13Details
TOYOTA 1125 18 JUN 26US89236TJK25Details
Boeing Co 2196US097023DG73Details
TOYOTA 47 12 JAN 33US89236TKR58Details
TOYOTA 4625 12 JAN 28US89236TKQ75Details
TOYOTA 5067497 10 JAN 25US89236TKP92Details
TOYOTA 48 10 JAN 25US89236TKN45Details
TOYOTA 545 10 NOV 27US89236TKL88Details
TOYOTA 455 20 SEP 27US89236TKJ33Details
TOYOTA 54 10 NOV 25US89236TKK06Details
HSBC Holdings PLCUS404280DR76Details
MPLX LP 52US55336VAL45Details
TOYOTA MTR CRUS89236TDR32Details
TOYOTA MTR CRUS89236TEW18Details
TOYOTA MTR CRUS89236TEM36Details
TOYOTA MTR CRUS89236TFT79Details
Morgan Stanley 3591US61744YAK47Details
TOYOTA MOTOR CREDITUS89236TGX72Details
TOYOTA MOTOR CREDITUS89236TGY55Details
TOYOTA MOTOR CREDITUS89236TGU34Details
TOYOTA MOTOR CREDITUS89236TGT60Details
TOYOTA 165 10 JAN 31US89236THX63Details
TOYOTA 8 09 JAN 26US89236THW80Details
TOYOTA MOTOR CREDITUS89236THP30Details
US89236THJ79US89236THJ79Details
US89236THG31US89236THG31Details
TOYOTA MOTOR CREDITUS89236TJF30Details

Understaning TRACON Pharmaceuticals Use of Financial Leverage

Leverage ratios show TRACON Pharmaceuticals' total debt position, including all outstanding obligations. In simple terms, high financial leverage means that the cost of production, along with the day-to-day running of the business, is high. Conversely, lower financial leverage implies lower fixed cost investment in the business, which is generally considered a good sign by investors. The degree of TRACON Pharmaceuticals' financial leverage can be measured in several ways, including ratios such as the debt-to-equity ratio (total debt / total equity), or the debt ratio (total debt / total assets).
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California. Tracon Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 19 people.
Please read more on our technical analysis page.

Pair Trading with TRACON Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if TRACON Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in TRACON Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with TRACON Stock

  0.73VALN Valneva SE ADRPairCorr

Moving against TRACON Stock

  0.59VERA Vera TherapeuticsPairCorr
  0.55VCYT VeracytePairCorr
  0.52DSGN Design TherapeuticsPairCorr
  0.49DRUG Bright Minds Biosciences TrendingPairCorr
  0.42SABSW SAB BiotherapeuticsPairCorr
The ability to find closely correlated positions to TRACON Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace TRACON Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back TRACON Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling TRACON Pharmaceuticals to buy it.
The correlation of TRACON Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as TRACON Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if TRACON Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for TRACON Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.

Other Consideration for investing in TRACON Stock

If you are still planning to invest in TRACON Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the TRACON Pharmaceuticals' history and understand the potential risks before investing.
Stocks Directory
Find actively traded stocks across global markets
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities

What is Financial Leverage?

Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.

Leverage and Capital Costs

The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.

Benefits of Financial Leverage

Leverage provides the following benefits for companies:
  • Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
  • It provides a variety of financing sources by which the firm can achieve its target earnings.
  • Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.
By borrowing funds, the firm incurs a debt that must be paid. But, this debt is paid in small installments over a relatively long period of time. This frees funds for more immediate use in the stock market. For example, suppose a company can afford a new factory but will be left with negligible free cash. In that case, it may be better to finance the factory and spend the cash on hand on inputs, labor, or even hold a significant portion as a reserve against unforeseen circumstances.

The Risk of Financial Leverage

The most obvious and apparent risk of leverage is that if price changes unexpectedly, the leveraged position can lead to severe losses. For example, imagine a hedge fund seeded by $50 worth of investor money. The hedge fund borrows another $50 and buys an asset worth $100, leading to a leverage ratio of 2:1. For the investor, this is neither good nor bad -- until the asset price changes. If the asset price goes up 10 percent, the investor earns $10 on $50 of capital, a net gain of 20 percent, and is very pleased with the increased gains from the leverage. However, if the asset price crashes unexpectedly, say by 30 percent, the investor loses $30 on $50 of capital, suffering a 60 percent loss. In other words, the effect of leverage is to increase the volatility of returns and increase the effects of a price change on the asset to the bottom line while increasing the chance for profit as well.